Statement from the Chief Public Health Officer of Canada on July 15, 2022


The COVID-19 pandemic continues to create stress and anxiety for many Canadians, especially those who do not have easy access to their usual support networks. Through the Wellness Together Canada online portal, people of all ages across the country can access immediate, free and confidential mental health and addictions supports 24 hours a day, seven days a week. PocketWell , a free companion app to the WTC Online Portal, offers another way to help Canadians access online resources about mental health and substance use, and measure and monitor aspects of their mental well-being.

OTTAWA (ON), July 15, 2022 /CNW/ – The Public Health Agency of Canada (PHAC) continues to monitor epidemiological indicators of COVID-19 to quickly detect, understand and communicate emerging issues of concern. Here is a brief summary of the latest national trends.

For additional data and analysis on COVID-19, PHAC publishes the following reports:

Nationwide, indicators of COVID-19 disease activity and severity have increased in recent weeks as Omicron’s BA.5 subline predominates in more regions across Canada. Compared to previous weeks, all indicators are increasing nationwide, from weekly case counts and lab test positivity to the average daily number of people with COVID-19 in hospitals across the country. Canada.

As we expect the SARS-CoV-2 virus to continue to evolve, PHAC maintains ongoing surveillance of circulating SARS-CoV-2 viruses in Canada and is currently closely monitoring several Omicron sublines that have demonstrated a growth advantage and additional immune evasion over the BA.1 and BA.2 sublines. Although the precise impacts are unknown, it is reasonable to expect a continued increase in the number of cases over the coming weeks, particularly due to the proportional increase in the BA.5 subline of Omicron among the sequenced viruses.

Although the latest serological survey data from the COVID-19 Immunity Task Force (CITF) indicate that the immunity acquired by infection has increased sharply Canada during the first five months of the Omicron wave, recent evidence suggests that most infected people remain at risk of reinfection with similar and other viruses of the Omicron lineage. This is particularly the case for people who are not yet vaccinated or whose COVID-19 vaccinations are not up to date. As such, keeping up to date with COVID-19 vaccines, including booster doses, continues to be very important in reducing the risk of hospitalization and death from COVID-19. Latest available vaccine effectiveness data Between May 09, 2022 and June 05, 2022when Omicron variant activity still predominated, indicate that persons vaccinated with a complete primary series plus one additional dose COVID-19 vaccines had an approximately four times lower hospitalization rate and a six times lower death rate, compared to unvaccinated people.

Yesterday marked another significant expansion of from Canada COVID-19 Vaccination Program, Health Canada authorizing first COVID-19 vaccine for use in children under 5 years of age. Moderna’s Spikevax mRNA COVID-19 vaccine (25 mcg) is now licensed for two-dose primary series use in children 6 months to 5 years of age. As well, from Canada The National Advisory Committee on Immunization (NACI) has reviewed clinical trial data on the safety, efficacy, and immune response generated by the Moderna Spikevax COVID-19 vaccine (25 mcg) in children in this group of children. age, as well as a review of epidemiological data on the spread and severity of COVID-19 in children under 5 years of age.

Right now, NACI has provided recommendations on the use of Moderna Spikevax COVID-19 vaccine (25 mcg) for children from 6 months to 5 years, including:

  • A first series of two doses Moderna Spikevax COVID-19 vaccine (25 mcg) can be offered children from 6 months to 5 years old who have no contraindication to the vaccine, with an interval of at least 8 weeks between the first and second dose.
  • A first series of three doses Moderna Spikevax COVID-19 vaccine (25 mcg) can be offered to children from 6 months to 5 years old who are moderately to severely immunocompromised and have no contraindications to the vaccine, with an interval of 4 to 8 weeks between each dose.

As this is a newly licensed COVID-19 vaccine in this age group, NACI recommends Moderna Spikevax COVID-19 vaccine (25 mcg) should not always be given on the same day as other vaccines and should be given 14 days before or after a different vaccine. This will help determine if a potential side effect could be due to the Moderna Spikevax COVID-19 vaccine (25 mcg) or another vaccine. Additionally, NACI recommends a shorter interval between Moderna Spikevax (25 mcg) vaccine administration and a different vaccine may be warranted in certain circumstances at the discretion of a health care provider.

With these recommendations, access to vaccination against COVID-19 is now expanded to include all people in Canada from 6 months and without contraindications. Going forward, health authorities and NACI experts will closely monitor the national rollout of the expanded pediatric program in Canada and continue to review accumulated evidence from international programs and studies. During this time, it is very important that we continue to support children and their caregivers to make informed decisions about COVID-19 vaccination, while respecting their choices and pace of decision-making.

Throughout the summer and as fall approaches, our best advantage is to continue to be vigilant with personal protective habits, as we maintain a state of readiness and prepare our surge capacity for ongoing and future response. At the individual level, preparation can best be achieved by keep COVID-19 vaccinations up to dateincluding obtaining booster doses as recommended, to be better protected against serious illness and other complications of COVID-19 infection, including post-COVID-19 status (also known as COVID long). At the same time, continuing to follow public health advice appropriate to local epidemiology and circumstances can help guide your individual and family risk assessment and the use of personal protective practices to reduce your risk of exposure and spreading the virus. Especially, properly wearing a well-fitting and well-constructed face mask, avoid clutterand get the best possible ventilation in interior spaces, are layers of protection that can reduce your risk in any setting. As always, stay home and away from others when you positive test using a rapid test, or if you are ill or have COVID-like symptoms, even if mild, you are advised to reduce the risk of spreading the virus.

We can also stay healthier by updating ourselves with other recommended vaccines and routine vaccines for children and adults. For more information on vaccination in your area, contact your local public health authoritieshealth care provider or other reliable and credible sources, such as and Canada.cawhich includes information to help Canadians understand benefits of being vaccinated against COVID-19.

Canadians can also go the extra mile by sharing credible Informations about COVID-19 Risks and Prevention Practices and measures to reduce COVID-19 in communities. Read my information document to learn more Information and resources on COVID-19 about ways to reduce risk and protect yourself and others, including information about COVID-19 vaccination.

SOURCE Public Health Agency of Canada

For further information: Media Relations, Public Health Agency of Canada, 613-957-2983 [email protected]


Comments are closed.